Baidu
map

Acta Neurol Scand:和肽素水平较高是TIA患者再发卒中的预测因素

2015-10-30 phylis 译 MedSci原创

背景:临床上,根据临床数据及血管影像学处理短暂性脑缺血(TIA),然而,一些生物标记物也能改善TIA患者的预后。方法:评估症状开始第一个24h内TIA患者血清和肽素,脂联素,新蝶呤,神经元特异性烯醇化酶,超敏C反应蛋白,IL-6,钠尿肽,S100β,肿瘤坏死因子-α和IL-1α水平以及患者临床特征。结果:在237名TIA患者中,12名(5%)患者7天内发生卒中,14名(6%)90天内发生卒中。分析

背景:临床上,根据临床数据及血管影像学处理短暂性脑缺血(TIA),然而,一些生物标记物也能改善TIA患者的预后。

方法:评估症状开始第一个24h内TIA患者血清和肽素、脂联素、新蝶呤、神经元特异性烯醇化酶、超敏C反应蛋白、IL-6、钠尿肽、S100β,肿瘤坏死因子-α和IL-1α水平以及患者临床特征。

结果:在237名TIA患者中,12名(5%)患者7天内发生卒中,14名(6%)90天内发生卒中。分析所有潜在的生物标记物,仅和肽素与7天内卒中再发(SR)显著相关,但与90天内卒中再发不相关。界值点13.8 pmol/L是良好的阴性预测值(97.4%)。大动脉粥样硬化(LAA)(HR 12.7, 95% CI:3.2-50.1)和和肽素≥13.8 pmol/l(HR 3.9,95% CI:1.01-14.4)是随访7天SR的独立预测因子。LAA仅是90天内SR的预测因子(HR 7.4, 95% CI 2.5-21.6)。ABCD31与7天和90天SR相关。和肽素和LAA相关性的正确诊断率为90.3%。

结论:血清和肽素是TIA患者预后的重要生物标记物。然而,TIA患者和肽素水平低于13.8 pmol/l及无LAA不是7天SR的风险因素,可在门诊进行处理。

原文出处:

Purroy F1, Suárez-Luis I1, Cambray S1,et al. The determination of copeptin levels helps management decisions among transient ischaemic attack patients. Acta Neurol Scand. 2015 Oct 16.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999591, encodeId=14bc1999591a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 01:55:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795686, encodeId=fde71e9568656, content=<a href='/topic/show?id=6abe1e434d6' target=_blank style='color:#2F92EE;'>#TIA患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17434, encryptionId=6abe1e434d6, topicName=TIA患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sun Jul 17 03:55:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849518, encodeId=4923184951837, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri May 27 01:55:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264218, encodeId=4a4c12642187b, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443397, encodeId=e09f144339e6c, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42006, encodeId=fbb64200608, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Fri Oct 30 21:57:00 CST 2015, time=2015-10-30, status=1, ipAttribution=)]
    2016-07-05 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999591, encodeId=14bc1999591a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 01:55:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795686, encodeId=fde71e9568656, content=<a href='/topic/show?id=6abe1e434d6' target=_blank style='color:#2F92EE;'>#TIA患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17434, encryptionId=6abe1e434d6, topicName=TIA患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sun Jul 17 03:55:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849518, encodeId=4923184951837, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri May 27 01:55:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264218, encodeId=4a4c12642187b, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443397, encodeId=e09f144339e6c, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42006, encodeId=fbb64200608, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Fri Oct 30 21:57:00 CST 2015, time=2015-10-30, status=1, ipAttribution=)]
    2016-07-17 马龙
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999591, encodeId=14bc1999591a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 01:55:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795686, encodeId=fde71e9568656, content=<a href='/topic/show?id=6abe1e434d6' target=_blank style='color:#2F92EE;'>#TIA患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17434, encryptionId=6abe1e434d6, topicName=TIA患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sun Jul 17 03:55:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849518, encodeId=4923184951837, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri May 27 01:55:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264218, encodeId=4a4c12642187b, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443397, encodeId=e09f144339e6c, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42006, encodeId=fbb64200608, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Fri Oct 30 21:57:00 CST 2015, time=2015-10-30, status=1, ipAttribution=)]
    2016-05-27 windight
  4. [GetPortalCommentsPageByObjectIdResponse(id=1999591, encodeId=14bc1999591a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 01:55:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795686, encodeId=fde71e9568656, content=<a href='/topic/show?id=6abe1e434d6' target=_blank style='color:#2F92EE;'>#TIA患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17434, encryptionId=6abe1e434d6, topicName=TIA患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sun Jul 17 03:55:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849518, encodeId=4923184951837, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri May 27 01:55:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264218, encodeId=4a4c12642187b, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443397, encodeId=e09f144339e6c, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42006, encodeId=fbb64200608, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Fri Oct 30 21:57:00 CST 2015, time=2015-10-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999591, encodeId=14bc1999591a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 01:55:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795686, encodeId=fde71e9568656, content=<a href='/topic/show?id=6abe1e434d6' target=_blank style='color:#2F92EE;'>#TIA患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17434, encryptionId=6abe1e434d6, topicName=TIA患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sun Jul 17 03:55:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849518, encodeId=4923184951837, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri May 27 01:55:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264218, encodeId=4a4c12642187b, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443397, encodeId=e09f144339e6c, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42006, encodeId=fbb64200608, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Fri Oct 30 21:57:00 CST 2015, time=2015-10-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1999591, encodeId=14bc1999591a7, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Jul 05 01:55:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795686, encodeId=fde71e9568656, content=<a href='/topic/show?id=6abe1e434d6' target=_blank style='color:#2F92EE;'>#TIA患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17434, encryptionId=6abe1e434d6, topicName=TIA患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sun Jul 17 03:55:00 CST 2016, time=2016-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849518, encodeId=4923184951837, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri May 27 01:55:00 CST 2016, time=2016-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264218, encodeId=4a4c12642187b, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443397, encodeId=e09f144339e6c, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Sun Nov 01 02:55:00 CST 2015, time=2015-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=42006, encodeId=fbb64200608, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Fri Oct 30 21:57:00 CST 2015, time=2015-10-30, status=1, ipAttribution=)]
    2015-10-30 梦想天空

    0

相关资讯

Neurology:和肽素有助判断缺血性卒中的预后

和肽素能够独立预测功能转归和死亡率 和肽素增高相比于那些已经确定的临床变量在预测转归和并发症上的作用尚不清楚。为此,瑞典伯尔尼大学神经内科的Gian Marco De Marchis博士等人进行了一项研究。研究结果在线发表在2013年3月6日的Neurology杂志上。研究结果显示:对于缺血性卒中患者,和肽素是除了卒中严重程度和年龄之外能够增加功能转归和3个月死亡预测效力的实用血液标志物。该研究

EJEM:和肽素(copeptin)或可用作急性冠脉综合征的生物标记物

      科学家最近发现一种名为和肽素的物质可以作为急性冠脉综合症非常有效的生物标记物。通过和肽素监测,研究人员可以迅速确定患者是否为心脏病发作。一项有902人参与的临床研究显示,通过和肽素检测方法可以大大提高心脏病确诊的准确性。 一位英国的医生表示,在医院中有类似胸口疼痛等心脏病疑似症状的患者中大概只有10%真正患有急性心脏病。这一生物标记物如能应用,将大大提高医院工

Stroke:和肽素可预测缺血性卒中患者血管事件的再发

背景和目的:和肽素作为精氨酸加压素原羧基末端的一部分,是心肌梗死和心衰患者预后的有用的标记物。高水平的和肽素与缺血性卒中和短暂性脑缺血发作(TIA)不良功能预后和死亡率升高相关。然而,和肽素是否能预测TIA和卒中后发生血管事件的风险尚不清楚。方法:招募了从2002年到2007年牛津血管研究中TIA或缺血性卒中患者,检测和肽素水平,并随访到2014年。应用Cox回归分析相关的再发血管事件的风险。结果

Baidu
map
Baidu
map
Baidu
map